The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI).
Denise Aysel Yardley
Consultant or Advisory Role - Novartis (U)
Linda D. Bosserman
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Nancy Walker Peacock
No relevant relationships to disclose
Anne Favret
No relevant relationships to disclose
Susan Kay Morgan
No relevant relationships to disclose
Victor M. Priego
No relevant relationships to disclose
J. David Bass
No relevant relationships to disclose
Paula L. Griner
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
John D. Hainsworth
No relevant relationships to disclose
Joyce O'Shaughnessy
Consultant or Advisory Role - Genentech; Novartis